Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.
Romeo S, Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina R, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, Rosendaal F, Kozlitina J, Pajukanta P, Pattou F, Valenti L. Romeo S, et al. Among authors: vespasiani gentilucci u. Res Sq [Preprint]. 2024 Feb 6:rs.3.rs-3878807. doi: 10.21203/rs.3.rs-3878807/v1. Res Sq. 2024. PMID: 38405802 Free PMC article. Preprint.
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A, Ostadreza M, Jamialahmadi O, Pelusi S, Rrapaj E, Casirati E, Passignani G, Norouziesfahani M, Sinopoli E, Baselli G, Meda C, Dongiovanni P, Dondossola D, Youngson N, Tourna A, Chokshi S, Bugianesi E; EPIDEMIC Study Investigators; Della Torre S, Prati D, Romeo S, Valenti L. Cherubini A, et al. Nat Med. 2023 Oct;29(10):2643-2655. doi: 10.1038/s41591-023-02553-8. Epub 2023 Sep 25. Nat Med. 2023. PMID: 37749332 Free PMC article.
IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids.
Sasidharan K, Caddeo A, Jamialahmadi O, Noto FR, Tomasi M, Malvestiti F, Ciociola E, Tavaglione F, Mancina RM, Cherubini A, Bianco C, Mirarchi A, Männistö V, Pihlajamäki J, Kärjä V, Grimaudo S, Luukkonen PK, Qadri S, Yki-Järvinen H, Petta S, Manfrini S, Vespasiani-Gentilucci U, Bruni V, Valenti L, Romeo S. Sasidharan K, et al. Cell Rep Med. 2024 Jan 16;5(1):101352. doi: 10.1016/j.xcrm.2023.101352. Cell Rep Med. 2024. PMID: 38232700 Free PMC article.
Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A, Ostadreza M, Jamialahmadi O, Pelusi S, Rrapaj E, Casirati E, Passignani G, Norouziesfahani M, Sinopoli E, Baselli G, Meda C, Dongiovanni P, Dondossola D, Youngson N, Tourna A, Chokshi S, Bugianesi E; EPIDEMIC Study Investigators; Della Torre S, Prati D, Romeo S, Valenti L. Cherubini A, et al. Nat Med. 2024 Apr;30(4):1212. doi: 10.1038/s41591-024-02817-x. Nat Med. 2024. PMID: 38267549 Free PMC article. No abstract available.
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
Marchetti A, Pelusi S, Marella A, Malvestiti F, Ricchiuti A, Ronzoni L, Lionetti M, Moretti V, Bugianesi E, Miele L, Vespasiani-Gentilucci U, Dongiovanni P, Federico A, Soardo G, D'Ambrosio R, McCain MV, Reeves HL, La Mura V, Prati D, Bolli N, Valenti L; EPIDEMIC Study Investigators. Marchetti A, et al. Among authors: vespasiani gentilucci u. Hepatology. 2024 Oct 1;80(4):816-827. doi: 10.1097/HEP.0000000000000839. Epub 2024 Mar 11. Hepatology. 2024. PMID: 38470216 Free PMC article.
Integrating PNPLA3 into clinical risk prediction.
Chen VL, Vespasiani-Gentilucci U. Chen VL, et al. Among authors: vespasiani gentilucci u. Liver Int. 2024 Sep 16. doi: 10.1111/liv.16103. Online ahead of print. Liver Int. 2024. PMID: 39282715 Review.
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.
Gallo P, De Vincentis A, Terracciani F, Falcomatà A, Pace Palitti V, Russello M, Vignone A, Alvaro D, Tortora R, Biolato M, Pompili M, Calvaruso V, Marzia V, Tizzani M, Caneglias A, Frigo F, Gesualdo M, Marzano A, Rosato V, Claar E, Villani R, Izzi A, Cozzolongo R, Cozzolino A, Airoldi A, Mazzarelli C, Distefano M, Iegri C, Fagiuoli S, Messina V, Ragone E, Sacco R, Cacciatore P, Masutti F, Crocé SL, Moretti A, Flagiello V, Di Pasquale G, Picardi A, Vespasiani-Gentilucci U. Gallo P, et al. Among authors: vespasiani gentilucci u. J Clin Med. 2024 Jul 6;13(13):3965. doi: 10.3390/jcm13133965. J Clin Med. 2024. PMID: 38999529 Free PMC article.
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
De Vincentis A, Ampuero J, Terracciani F, D'Amato D, Gerussi A, Cristoferi L, Cazzagon N, Bonaiuto E, Floreani A, Calvaruso V, Cadamuro L, Degasperi E, Morgando A, Vanni E, Lleo A, Colapietro F, Alvaro D, Castellaneta A, Labanca S, Viganò M, Distefano M, Pace Palitti V, Ricci C, De Matthaeis N, Marzioni M, Gómez-Dominguez E, Montero JL, Molina E, Garcia-Buey L, Casado M, Berenguer M, Conde I, Simon MA, Fuentes J, Costa-Moreira P, Macedo G, Jorquera F, Morillas RM, Presa J, Sousa JM, Gomes D, Santos L, Olveira A, Hernandez-Guerra M, Aburruza L, Santos A, Carvalho A, Uriz J, Gutierrez ML, Perez E, Chessa L, Pellicelli A, Marignani M, Muratori L, Niro GA, Brunetto M, Ponziani FR, Pompili M, Marra F, Galli A, Mussetto A, Alagna G, Simone L, Bertino G, Rosina F, Cozzolongo R, Russello M, Baiocchi L, Saitta C, Terreni N, Zolfino T, Rigamonti C, Vigano R, Cuccorese G, Pozzoni P, Pedone C, Grasso S, Picardi A, Invernizzi P, Sacco R, Izzi A, Fernandez-Rodriguez C, Vespasiani-Gentilucci U, Carbone M; RECAPITULATE Investigators. De Vincentis A, et al. Among authors: vespasiani gentilucci u. Clin Gastroenterol Hepatol. 2024 May 22:S1542-3565(24)00482-8. doi: 10.1016/j.cgh.2024.05.008. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38782175
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
De Vincentis A, Tavaglione F, Namba S, Kanai M, Okada Y, Kamatani Y, Maurotti S, Pedone C, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. De Vincentis A, et al. Among authors: vespasiani gentilucci u. Aliment Pharmacol Ther. 2024 Jun;59(11):1402-1412. doi: 10.1111/apt.17953. Epub 2024 Mar 18. Aliment Pharmacol Ther. 2024. PMID: 38497224
131 results